These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30101402)

  • 1. Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.
    Wills B; Brahmer JR; Naidoo J
    Curr Treat Options Oncol; 2018 Aug; 19(9):46. PubMed ID: 30101402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
    Chow LQ
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
    Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y
    Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
    Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S
    Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy.
    Shafqat H; Gourdin T; Sion A
    Semin Oncol; 2018 Jun; 45(3):156-163. PubMed ID: 30348532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer.
    Rebuzzi SE; Leonetti A; Tiseo M; Facchinetti F
    Immunotherapy; 2019 Aug; 11(12):993-1003. PubMed ID: 31319742
    [No Abstract]   [Full Text] [Related]  

  • 13. [Not Available].
    Mignard X; Chaabane N; Fallet V; Wislez M
    Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
    Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 checkpoint inhibition: Toxicities and management.
    Hahn AW; Gill DM; Agarwal N; Maughan BL
    Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
    Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
    BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm.
    Breimer LH; Nousios P; Olsson L; Brunnström H
    Scand J Clin Lab Invest; 2020 Sep; 80(5):360-369. PubMed ID: 32238062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
    Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
    Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.